Social anxiety disorder under scrutiny

Depression and Anxiety

Volumn 11, Issue 3, 2000, Pages 93-98

  Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Benzodiazepine; Monoamine oxidase inhibitor; Paroxetine; Selective serotonin reuptake inhibitor; Social anxiety disorder

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CLONAZEPAM; FLUVOXAMINE; GABAPENTIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGORAPHOBIA; ANXIETY NEUROSIS; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; DEPRESSION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HUMAN; PANIC; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECURRENT DISEASE; SOCIAL PHOBIA;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0034129045     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(2000)11:3<93::AID-DA2>3.0.CO;2-7     Document Type: Article

References (33)

1. Allgulander C. 1999. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100:193-198.
2. Baldwin D, Bobes J, Stein DJ, Schanvächter I, Faure M, on behalf of the Paroxetine Study Group. 1999. A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social aaxiety disorder. BrJ Psychiatry 178:120-126.
3. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG. 1998. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Int Clin Psychopharmacol 59 (suppl):54-60.
4. Beidel DC, Turner SM, editors. 1998. Shy children and phobic adults: the nature and treatment of social phobia. Washington DC: American Psychological Association, p 45-47.
5. Burrows G, Evans L, Baumhackl U. 1997. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71-80.
6. Connor KM, Davidson JRT, Potts NL, Tupler LA, Miner CM, Malik ML, Book SW, Colket JT, Ferrell F. 1995. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 18:373-378.
7. Connor KAI, Davidson JRT, Churchill LE, Sherwood A, Foa EB, Weisler RH. Psychometric properties of the social phobia inventory (SPIN): a new self-rating scale. BrJ Psychiatry (in press).
8. Davidson JRT, Hughes DL, George LK, Blazer DG. 1993. The epidemiology of social phobia. Findings from the Duke Epidemiologie Catchment Area Study. Psychology Medicine 23: 709-718.
9. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. 1994. Washington DC: American Psychiatric Association.
10. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U. 1995. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A doubleblind placebo-controlled study. Acta Psychiatr Scand 92:351-358.
11. Fyer AJ, Mannuzza S, Chapman TF, Liebowitz AIR, Klein DF. 1993. A direct interview family study of social phobia. Arch Gen Psychiatry 50:286-293.
12. Gelernter CS, Uhde TW, Cimbolic O, Arnoff DB, Vittone BJ, Tancer AIE, BartkoJJ. 1991. Cognitive-behavioural and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 48:938-945.
13. Heimberg RG, Liebowitz AIR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre AI, Fallon B, Klein DF. 1998. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55:1133-1141.
14. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. 1995. Sertraline for social phobia. A double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368-1371.
15. Kendler KS, Neale MC, Kassier RC, Heath AC, Eaves LJ. 1992. The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. Arch Gen Psychiatry 49: 273-281.
16. Lépine J-P, Lellouch J. 1995. Classification and epidemiology of social phobia. Eur Arch Psychiatry Clin Neurosci 244:290-296.
17. Liebowitz MR, Schneier F, Campeas R et al. 1992. Phenelzine versus atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49:290-300.
18. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. 1997. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17:255-260.
19. Magee WJ, Eaton VV, Wittchen H-U, McGonagle KA, Kessler RC. 1996. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53:159-168.
20. Mannuzza S, Schneier FR, Chapman TF, Liebowitz MR, Klein DF, Fyer AJ. 1995. Generalized social phobia. Arch Gen Psychiatry 52:230-237.
21. Noyes R, Moroz G, Davidson JRT, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH. 1997. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 17:247-254.
22. Pande AC, Davidson JR, Jefferson V, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. 1999. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341-348.
23. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. 1998. Placebo-controlled trial of moclobemide in social phobia. BrJ Psychiatry 172:70-77.
24. Stein MB, Charrier MJ, Hazen AL, Kroft CD, Châle RA, Cote D, Walker JR. 1996. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 16:218-222.
25. Stein MB, Chattier MJ, Hazen AL, Kozak MV, Tancer ME, Lander S, Furer P, Chubaty D, Walker JR. 1998a. A direct-interview family study of generalized social phobia. Am J Psychiatry 155:90-97
26. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I 1998b. Paroxetine treatment of generalised social phobia. A randomised, double-blind, placebo-controlled study. JAMA 280:708-713.
27. Stein MB, Fyer AJ, Davidson JRT, Pollack MH. 1999. Fluvoxamine treatment of social phobia: a double-blind placebo-controlled study. Am J Psychiatry 156:756-760.
28. Tenth International Classification of Diseases, Classification of Mental and Behavioural Disorders. 1992. GenevaAVbrld Health Organization.
29. Turner SM, Beidel DC, Joerb RG. 1994. Social phobia: a comparison of behaviour therapy and atenolol. J Consult Clin Psychol 67:350-358.
30. van Vliet IM, den Boer JA, Westenberg HG. 1992. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2:21-29.
31. van Vliet LM, den Boer JA, Westenberg HGM. 1994. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115:128-134.
32. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. 1992. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. BrJ Psychiatry 161:353-360.
33. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R. 1996. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 11 (suppl 3):83-88.